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Background: Myeloid-derived suppressor cells (MDSCs) are among the major obstacles that adjuvants for cancer
vaccines have to overcome. These cells cross-present tumor-associated antigens (TAA) to naive T lymphocytes with
a tolerogenic outcome. Very Small Size Proteoliposomes (VSSP) is used as adjuvant by four therapeutic cancer
vaccines currently in Phase I and II clinical trials. We previously found that VSSP reduces the suppressive function of
MDSCs, then activating antigen-specific CTL responses in tumor-bearing (TB) mice, with the consequent reduction
of tumor growth. However the mechanistic explanation for the immunomodulatory effect of this adjuvant in TB
hosts has not been addressed before.
Methods: TB mice were inoculated with VSSP and MDSCs isolated and characterized by their expression of Arg1
and Nos2 genes by RT-PCR. The effect of VSSP on antigen cross-presentation by MDSCs, regulatory T cells (Tregs)
expansion and MDSCs differentiation towards dendritic cells (DCs) was analyzed by FACS. Student’s t test or ANOVA
and Tukey’s tests were used for statistical analyses.
Results: After inoculating VSSP into TB mice, a significant reduction of Arg1 and Nos2 gene expression was
observed in recovered MDSCs. Concurrently the ability of these cells to induce down-regulation of CD3ζ chain on
T cells was lost. Likewise in mice inoculated with the adjuvant lower percentages of Tregs were detected. In vitro,
VSSP treatment was enough to differentiate MDSCs into phenotypically mature DCs, eliminating the former
suppressive effect. Noteworthy, in vivo administration of VSSP to OVA-expressing (EG.7) TB mice abrogated this
model antigen cross-presentation by splenic MDSCs. Similar results were obtained even when OVA antigen was
administered into these TB mice formulated in VSSP. On the contrary, immunization with the same protein in polyI:
C did not change the percentage of MDSCs expressing SIINFEKL/H-2Kb complexes, whereas a concomitant injection
of VSSP aborted the limitations of polyI:C in this setting.
Conclusions: Altogether, these results indicate that VSSP has the peculiar capacity of inhibiting TAA cross-presentation
and certain suppressive mechanisms on MDSCs which in turn, combined with the ability to induce differentiation of
these cells into antigen-presenting cells (APCs), sustains this adjuvant as an ideal immunomodulator for cancer
immunotherapy.
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The induction of an effective CTL activity is difficult
to achieve in the immunosuppressive environment of a
tumor. Tregs, MDSCs and tumor-associated macrophages
have been recognized as the main inhibitory populations
recruited by tumors with relevant contribution to the
dampening of antitumor immune response [1-3].
Particularly, MDSCs are a heterogeneous population of
myeloid origin, which express CD11b and Gr1 markers in
mice [4] but their phenotype in human cancers is ra-
ther diverse [5,6]. MDSCs-mediated suppression of CD8+
T cell [7-9] and NK cell [10,11] functions has been well
characterized. In contrast, the inhibition of CD4+ T cell
responses remained elusive until a recent work of Nagaraj
et al. in which the authors demonstrate that antigen-
specific CD4+ T cells are suppressed only by MCH II-
expressing MDSCs [12]. Although the mechanisms of
MDSCs-mediated suppression are quite diverse, there is a
general acceptance of the important role of L-arginine
metabolizing enzymes, arginase (ARG) and nitric oxide
synthase (NOS), with the Nox family of phagocytic oxi-
dases [4,13,14]. It has been shown that splenic MDSCs
can cross-present tumor antigens to CD8+ T cells, which
leads to tolerance induction [15]. Furthermore, the im-
munosuppressive network associated to cancer is rein-
forced by MDSCs that not only expand Tregs [16,17] but
can also differentiate into tumor-associated macrophages
within the tumor microenvironment [18,19].
Considering this complex scenario, antitumor immuno-
therapy requires not only of relevant antigens but also of
suitable immunomodulators to overcome tumor-induced
immunosuppression. Compounds like docetaxel, all-trans
retinoic acid and synthetic oligodeoxynucleotides con-
taining unmethylated CpG motifs (CpG ODN) accelerate
the differentiation of MDSCs into mature leukocytes
[20-23]. Moreover, some adjuvants are able to reduce the
inhibitory function of tumor-induced MDSCs [23-25].
Among these, we have previously reported the VSSP,
which is a nanoparticulated adjuvant obtained by the
combination of outer membrane vesicles from Neisseria
meningitidis (containing TLR2 and TLR4 agonists) and
GM3 ganglioside [26]. This adjuvant induces DCs matu-
ration and antigen cross-presentation to CD8+ T cells in
tumor-free mice [27,28]. More recently, we demonstrated
that VSSP protects CTL responses specific for the nomi-
nal antigen not only in TB mice but also in the context
of severe leukopenia [24,29]. Currently four therapeutic
cancer vaccines using this product as adjuvant are in
clinical research. Two of the formulations, based on the
epidermal growth factor receptor [30] and the vascular
endothelial growth factor [31] recombinant proteins, are in
Phase I clinical trials. Other two candidates, a human papi-
lloma virus peptide vaccine [32] and a gonadotropin relea-
sing hormone-based vaccine [33], have already finishedtheir safety and immunogenicity studies and are currently
being tested in Phase II trials in women with high-grade
cervical intraepithelial neoplasia and in prostate tumor pa-
tients, respectively [34]. Moreover, an ongoing physician-
lead trial in patients with metastatic renal cell carcinoma
intends to evaluate the effect of VSSP on MDSCs-media-
ted immunosuppression.
The aim of the present research was to assess the
influence of VSSP on the classical suppressive mecha-
nisms of MDSCs. A significant reduction in the expression
of Arg1 and Nos2 genes was observed as a consequence of
VSSP inoculation. This could be related with the observa-
tion that MDSCs from TB mice injected with the adjuvant
lost their ability to down-regulate CD3ζ chain on T cells.
Simultaneously, we detected a lower percentage of Tregs
in these mice as well as a higher expression of CD62L on
T lymphocytes. Of interest was the observation that VSSP
induced differentiation of MDSCs towards DCs expressing
maturation markers, but the most surprising result was
the inhibition caused by VSSP on cross-presentation of
TAA by splenic MDSCs. Our results suggest that VSSP
could be used during immunotherapy to modulate
MDSCs-mediated suppression of antitumor response, in-
cluding the expansion of Tregs.
Results
VSSP administration into TB mice potentiates CTL
responses and skews Th differentiation patterns
We have previously shown that VSSP administration into
MCA203 TB mice significantly reduces these tumors’
growth [24]. To understand the mechanisms associated
with the antitumor effect of VSSP, we began by studying
the effector T cell responses in these mice. MCA203 TB
mice displayed an impaired CTL response to OVA, formu-
lated with polyI:C as adjuvant, relative to vaccinated tumor-
free mice (Figure 1A and Additional file 1: Figure S1A).
Interestingly, when TB mice injected with OVA/polyI:C
additionally received three doses of VSSP alone, the de-
tected antigen-specific CTL response was significantly
higher than in TB mice non-treated with the adjuvant and
even superior than in tumor-free mice vaccinated with
OVA/polyI:C (Figure 1A and Additional file 1: Figure S1A).
Considering that VSSP is a Th1-prone adjuvant, we ex-
amined whether it was able to change the tumor-induced
polarization of TAA-specific Th cells (Additional file 1:
Figure S1B). Splenocytes from VSSP-treated or untreated
MCA203 TB mice were in vitro stimulated with bone mar-
row (BM)-derived DCs pulsed with tumor lysates, obtained
from MCA203 or 3LL-D122 (negative control) cell lines,
and the production of IFN-γ, IL-4 and IL-17 by CD4+
T cells was measured by intracellular staining. As shown in
Figure 1B, TAA-specific Th cells from non-treated TB mice
produced mainly IL-4 or IL-17, whereas in VSSP-treated
TB mice IL-4+ Th cells were undetectable. A significant
Figure 1 VSSP modulates Th differentiation and protects CTL responses in TB mice. Mice bearing MCA203 tumors were s.c. inoculated
with three doses of VSSP, or left untreated. (A) Mice were also vaccinated with OVA protein mixed with polyI:C and in vivo CTL response was
measured. Graph shows the specific lysis, as a percentage of the control (tumor-free mice). Data are represented as mean of three individual
mice ± SD. Two experiments with similar results were done. (B) Splenocytes from MCA203 TB mice, treated or not with VSSP, were stimulated
in vitro with BM-DCs, previously pulsed with tumor lysates obtained from MCA203 and 3LL-D122 tumor cell lines. Production of IL-4, IL-17 and
IFN-γ was detected by intracellular staining after 96 h stimulation. Graphs indicate the percentage of cells producing each cytokine, within the
CD4+ T cells gate, for six individual mice belonging to two different experiments. Statistical analyses were performed with ANOVA and Tukey’s
tests (A) or Kruskal-Wallis and Dunn’s tests (B).
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observed in VSSP-treated TB mice, associated with an in-
crease in IFN-γ/IL-17 double positive cells (Figure 1B).
Likewise, changes in the functionality of tumor-infiltra-
ting lymphocytes (TILs) derived from MCA203 TB mice,Figure 2 Effector functions of TILs are improved as a consequence of
days 11, 12 and 18. On day 22, the s.c. tumors were extracted and TILs wer
for 72 h with the MCA203 tumor cell line, or MB16F10 negative control. IFN
(B) Non-specific stimulation of TILs with Con A mitogen was additionally p
assay. Graphs indicate the mean of the number of IFN-γ spots from one ex
nificant differences were detected with Student’s t test.inoculated or not with VSSP, were evaluated. As shown in
Figure 2A, a higher frequency of IFN-γ secreting CD8+
TILs was detected in VSSP-treated TB mice after specific
in vitro stimulation with the MCA203 tumor cell line. As
expected, no CD8+ T cell response was observed underVSSP inoculation. MCA203 TB mice were inoculated with VSSP on
e isolated. (A) Tumor-specific response of CD8+ TILs after stimulation
-γ production by 106 CD8+ TILs was evaluated with ELISPOT assay.
erformed and the IFN-γ production was also evaluated by ELISPOT
periment representative of two (T: tumor and V: VSSP). Statistically sig-
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indicating that VSSP potentiated tumor-specific CD8+
T cell activation. In addition, VSSP reduced the functional
impairment caused by MCA203 tumor on TILs, as dem-
onstrated through the mitogenic stimulation with Con A
(Figure 2B). Overall, the interference with tumor-induced
suppression of CD4+ and CD8+ T cell responses, due to
VSSP administration, could be contributing to the antitu-
mor activity of this adjuvant in MCA203 TB mice.
Tumor-promoted recruitment of Tregs is impaired by
VSSP even in a context of increased numbers of MDSCs
It has been formerly demonstrated that MCA203 sarco-
mas induce the accumulation of suppressive MDSCs in
the spleen and tumor microenvironment [7,24]. Presently,
a corroboration of our previous results [24] demonstrating
that mice bearing MCA203 tumors injected with VSSP
(Additional file 1: Figure S1B) almost duplicate splenic
CD11b+Gr1+ cells, compared to untreated TB mice, was
achieved (data not shown). However, CD11b+Gr1+ cells
isolated from these VSSP-inoculated TB mice were pheno-
typically similar to those from VSSP-injected tumor-free
mice and different from untreated tumor-induced counter-
parts (Additional file 2: Figure S2A).
Looking at Tregs frequency, as expected from the litera-
ture, an increase of splenic CD4+CD25+ T cells expressing
Foxp3 was detected, from 8.75 ± 0.80% in tumor-freeFigure 3 VSSP inhibits tumor-mediated expansion of Tregs in mice w
were analyzed by FACS in VSSP-inoculated MCA203 TB mice, in comparison
inoculated with VSSP was also studied. Tregs percentages are referred to th
in two representative mice per group. (B) Data are expressed as mean ± SD
applied for statistical comparison. Data are representative of two experimencontrol mice to 14.80 ± 1.17% in MCA203 TB mice
(Figure 3A and B), connecting with one of the proposed
mechanisms for MDSCs mediated-suppression (i.e. the
expansion of Tregs that reinforce the suppression of
tumor-specific responses) [16,17]. Remarkably, in VSSP-
treated TB mice, in which the percentages of CD11b+Gr1+
cells were higher than in untreated TB mice, we found a
significant reduction in the percentages of splenic Tregs
(Figure 3A and B). In fact, no difference in Tregs fre-
quencies was observed between TB mice inoculated with
VSSP and tumor-free control mice. Additionally, the
inoculation of VSSP in tumor-free mice did not modify
the normal percentages of Tregs (Figure 3B), suggesting
that this adjuvant does not have a direct effect on Tregs
in vivo.
Interference of VSSP with the classical suppressive
mechanisms of MDSCs
Our previous results indicate that VSSP administration
to MCA203 TB mice reduces the suppression exerted by
tumor-induced splenic MDSCs on CD8+ T cells specific
for TAA [24]. Similarly, IFN-γ release and lytic activity
of OVA-specific CD8+ T cells were significantly inhibited
by MDSCs isolated from MCA203 TB mice, whereas
CD11b+Gr1+ cells obtained from VSSP-treated counter-
parts were non suppressive (Additional file 2: Figure S2B
and C). To increase our understanding of the effect ofith high percentages of MDSCs. Splenic CD4+CD25+Foxp3+ Tregs
to untreated TB mice or tumor-free mice. A group of tumor-free mice
e gate of CD4+ T cells. (A) Dot plot graphs show the staining of Tregs
of five individual mice per group. ANOVA and Tukey’s tests were
ts with similar results.
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chanisms associated with the suppressive function of these
cells were addressed following the schedule depicted in
Additional file 1: Figure S1B.
Among the negative effects of MDSCs on T lym-
phocytes, the down-regulation of both CD3ζ chain and
the homing molecule CD62L has been widely described
[35,36]. Thus, the expression of these molecules on T cells
from MCA203 TB mice, inoculated or nor with VSSP, was
determined. Notably, in vivo VSSP reduced the tumor-Figure 4 (See legend on next page.)induced down-regulation of CD3ζ chain on both CD4+
and CD8+ T cells (Figure 4A and B). Likewise, down-
regulation of CD62L on T cell populations was diminished
in TB mice treated with VSSP (Figure 4C). Considering in-
dividually normalized data related to the percentage of
MDSCs, again Tregs frequency was significantly lower in
MCA203 TB mice injected with VSSP than in untreated
TB mice (Figure 4D), reinforcing that VSSP could be re-
ducing the capacity of tumor-induced MDSCs to expand
Tregs.
(See figure on previous page.)
Figure 4 Suppressive mechanisms of MDSCs are dampened by VSSP. Mice were treated as described in Figure 2. FACS analyses of the
down-regulation of CD3ζ chain on CD8+ (A) and CD4+ (B) T cells, as well as CD62L on T cells (C), were performed in splenocytes from five
individual mice per group. Data were normalized by the percentage of MDSCs in each mouse. The reduction in Tregs frequency caused by VSSP
was further corroborated and resulted more obvious after the normalization procedure (D). Statistical comparisons between groups were done
with Student’s t test for CD62L expression and Tregs percentages, whereas Mann-Whitney’s U test was used to analyze down-regulation of
CD3ζ chain. (E-F) MDSCs immunomagnetically enriched from the spleens of VSSP-injected or untreated MCA203 TB mice were cultured at 20%
with splenocytes from OTI transgenic mice, in the presence of relevant peptide. Histograms show the expression of CD3ζ chain on CD8+ T cells
specifically stimulated with SIINFEKL peptide in the presence or absence of MDSCs. Further characterization of MDSCs isolated from each
experimental group was done by RT-PCR and the reduction of Arg1 (G) and Nos2 (H) gene expression is represented in bar graphs. Three
replicates of CD11b+Gr1+ cells isolated from pools of three mice per group were included in the RT-PCR analysis. (I) The capacity of MDSCs to
behave as APCs during Con A-stimulated IFN-γ production by CD8+ T cells was measured through ELISPOT assay. CD8+ T cells and CD11b+Gr1+
cells were isolated from TB mice, either treated or not with the adjuvant, and cocultured for 72 h in the presence of Con A mitogen. Graph
indicates the mean ± SD of the number of IFN-γ spots per 105 CD8+ T cells from one experiment representative of two (T: tumor and V: VSSP).
(G-I) The multiple comparisons of mean values were executed with ANOVA and Tukey’s tests.
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to down-regulate CD3ζ chain on CD8+ T cells, OTI
splenocytes were stimulated with SIINFEKL peptide in the
presence of 20% MDSCs derived from different sources.
As shown in Figure 4E, MDSCs isolated from MCA203
TB mice effectively down-regulated CD3ζ chain on anti-
gen-specific CD8+ T cells (2.9 fold of reduction). In con-
trast, MDSCs derived from VSSP-inoculated TB mice
were not able to down-regulate this key molecule for TCR
signaling (Figure 4F). A further comparison by RT-PCR of
CD11b+Gr1+ cells isolated from MCA203 TB mice, either
inoculated or not with VSSP, evidenced a significant
reduction of Arg1 and Nos2 gene expression as a conse-
quence of VSSP treatment (Figure 4G and H). It has been
extensively validated that ARG1 and NOS2 enzymes are
key players for MDSCs suppressive capacity and, among
other effects, contribute to CD3ζ chain down-regulation
on T cells (revised in [14]).
Another feature of MDSCs is their impaired function as
APCs. Thus, we wonder whether the capacity of MDSCs
to behave as APCs could be enhanced by inoculating
VSSP into MCA203 TB mice. Con A is a well-known
mitogen that requires APCs to achieve an efficient activa-
tion of T cells [37]. Therefore, CD8+ T cells purified from
either VSSP-inoculated or untreated MCA203 TB mice
were stimulated with Con A in the presence of the cor-
responding MDSCs. MDSCs derived from untreated TB
mice failed to stimulate Con A-induced production of
IFN-γ by these effector cells, whereas MDSCs purified
from VSSP-inoculated TB mice significantly increased the
production of this cytokine by CD8+ T cells, regardless of
the origin of these lymphocytes (Figure 4I). These results
indicate that MDSCs from VSSP-treated TB mice could
be functionally more differentiated to mature APCs.
In vitro treatment of MDSCs with VSSP induces their
differentiation and loss of suppressive activity
Considering that in vivo administration of VSSP modi-
fies tumor-induced MDSCs to display APCs functions,we hypothesized that probably the incubation of these
MDSCs with the adjuvant in vitro will induce their dif-
ferentiation to mature APCs. Based on our previous ex-
periments in which VSSP inoculation in vivo promoted
differentiation of adoptively transferred tumor-induced
MDSCs to DCs and not to macrophages [24], we fo-
cused our analysis particularly on differentiation towards
CD11c+ DCs in vitro. A more than 2 fold increase was
detected in both, percentage and mean fluorescence inten-
sity (MFI) of CD11c+ cells, within EL4-induced MDSCs
treated in vitro with VSSP (p = 0.001 and p = 0.002, re-
spectively) (Figure 5A and B). Furthermore, incubation
with VSSP also augmented the expression of CD40 and
CD86 molecules in these MDSCs, indicating a more
mature stage of the cells (Figure 5A and B). A higher MFI
associated to CD11b marker was seen additionally on
VSSP-treated MDSCs. Similar results were obtained
with MDSCs isolated from EG.7 and MCA203 TB mice
(Additional file 3: Figure S3). Looking at the modification
of the functional activity, we found that VSSP treatment
in vitro significantly reduced the suppression of T cell pro-
liferation mediated by MDSCs, isolated from these TB
mice (Figure 5C).
The next question to address was whether another
widely used adjuvant, polyI:C, has a VSSP-like effect on
MDSCs differentiation to DCs. VSSP caused a higher
increase than polyI:C in CD11b (3.18 vs 2.21 fold) and
CD11c (3.02 vs 2.06 fold) molecules on tumor-induced
MDSCs. Moreover, polyI:C did not significantly change
the expression of Gr1 (1.1 fold) and CD40 (0.75 fold)
whereas VSSP provoked near 2 fold increase in both
markers (Additional file 4: Figure S4A and B). Accor-
dingly, incubation of EL4-induced MDSCs with polyI:C
caused a reduction in the suppressive capacity of these
cells, but to a significantly lesser extent than VSSP
(Figure 5D).
To complete this study we tested the in vitro effect of
VSSP on BM-MDSCs. When VSSP was added during
differentiation of BM precursors with GM-CSF the
Figure 5 VSSP induces differentiation of tumor-promoted MDSCs towards DCs in vitro. Highly purified MDSCs from the spleen of EL4 TB
mice were incubated for 24 h with VSSP. (A-B) Expression of CD11c, CD11b, CD40 and CD86 was evaluated by FACS within the CD11b+Gr1+
gate. (C-D) Inhibition of T cell proliferation was assessed by the culture of 40% in vitro-treated MDSCs with splenocytes from naive mice in the
presence of Con A. (C) Effect of VSSP on the functional activity of MDSCs induced by EL4 and MCA203 tumors. (D) MDSCs from EL4 TB mice
were also cultured in vitro with polyI:C or LPS and their suppressive activity was compared with VSSP-treated MDSCs. ANOVA and Tukey’s tests
were employed for statistical comparison. These experiments were repeated three times with similar results.
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changed (Figure 6A), although it promoted a phenotypic
modification of these cells (Additional file 5: Figure S5).
However, the treatment of already differentiated BM-
MDSCs with VSSP effectively abrogated their suppressive
activity (Figure 6B). Resembling the results obtained with
tumor-induced splenic MDSCs, BM-MDSCs incubatedwith VSSP showed a higher expression of CD11c, CD11b,
Gr1 and CD40 than untreated control cells (Figure 6C).
Stimulation of BM-MDSCs with polyI:C caused a similar
modification than VSSP in the former markers, except for
CD40 which expression was not changed by polyI:C and
increased 2 fold with VSSP (Figure 6C). The suppression
of T cell proliferation by BM-MDSCs was also completely
Figure 6 Suppressive phenotype and function of BM-MDSCs are abolished after 24 h culture with VSSP. (A) BM precursors were cultured
with 40 ng/mL of GM-CSF for four days, in the presence or absence of VSSP. The capacity of these MDSCs (10% of the effector splenocytes) to
inhibit Con A-induced proliferation of T cells was next evaluated. (B-C) BM-MDSCs differentiated in vitro only with GM-CSF were treated with VSSP,
polyI:C or LPS for an additional 24 h. Afterward, the suppressive activity (B) and the phenotype within the CD11b+Gr1+ gate (C) were studied as
mentioned above. Statistical differences in bar graphs were detected with ANOVA and Tukey’s tests. Two repetitions of this experiment were
done with similar outcome.
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the mild effect it provoked on tumor-induced MDSCs
(Figure 6B).
Finally, since VSSP contains a TLR4 agonist, an ad-
ditional comparison with bacterial lipopolysaccharide
(LPS) was performed in these experimental settings. As
shown in Additional file 4: Figure S4A and C, LPS treat-
ment of tumor-induced MDSCs also caused a 2 foldincrease in the expression of CD11b, Gr1 and CD11c
molecules, similar to the effect of VSSP. However, LPS
was unable to up-regulate maturation markers like CD40
in these MDSCs (Additional file 4: Figure S4C) and, more
importantly, did not modify their suppressive activity
(Figure 5D). Additionally, the incubation of BM-MDSCs
with LPS did not significantly change the expression of
CD11c, CD11b, Gr1 and CD40 molecules (Figure 6C)
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suppress the proliferation of T cells (Figure 6B). Taken
together, these results suggest that the effect of VSSP on
differentiation of MDSCs into DCs is not a common cha-
racteristic of any TLR4 agonist, but a particular property
of VSSP.
VSSP inhibits cross-presentation of TAA antigens by
splenic CD11b+Gr1+ cells
Accordingly to previous findings that splenic CD11b+Gr1+
cells can cross-present tumor-antigens and tolerize specific
CD8+ T lymphocytes [15], a similar experimental setting
was selected to analyze whether VSSP could hamper this
important process for tumor-induced immunosuppressionFigure 7 Cross-presentation of TAA by splenic MDSCs is abrogated in
injected with VSSP and cross-presentation of the OVA peptide SIINFEKL w
last dose of the adjuvant. (A) Histograms show the staining with the mAb
cells for one representative mouse per group. (B) Mean ± SD of the perce
(n = 9 to n = 15 individual mice per group belonging to three replicated e
protein mixed with VSSP or polyI:C. Another group of TB mice was inocula
mice were included as negative controls. Cross-presentation of OVA antig
independent experiments. Statistical analyses were performed with ANOV(Additional file 1: Figure S1C). In fact, SIINFEKL peptide
presented in H-2Kb molecules was detected with a specific
Ab on splenic CD11b+Gr1+ cells from EG.7 TB mice
(Figure 7A, B and C). Remarkably, the treatment of
EG.7 TB mice with VSSP reduced to undetectable levels
the cross-presentation of OVA, as a model tumor antigen,
by splenic CD11b+Gr1+ cells, comparable to the values
obtained for MDSCs isolated from EL4 TB mice, a con-
trol tumor lacking OVA expression (Figure 7A and B).
Cross-presentation of OVA-derived SIINFEKL peptide
by MDSCs subpopulations in vivo was also further ana-
lyzed. As shown in Additional file 6: Figure S6, both
monocytic MDSCs (M-MDSCs, CD11b+Gr1lo) and poly-
morphonuclear MDSCs (PMN-MDSCs, CD11b+Gr1hi)VSSP-inoculated TB mice. (A-B) EL4 and EG.7 TB mice were
as detected by FACS on splenic CD11b+Gr1+ cells, two days after the
specific for H-2Kb-SIINFEKL peptide complexes on gated CD11b+Gr1+
ntages of MDSCs expressing OVA peptide bound to MHC I molecule
xperiments). (C) Mice with EG.7 tumors were vaccinated with OVA
ted with VSSP and additionally received OVA/polyI:C vaccine. EL4 TB
en was analyzed as described above. These data are from two
A and Tukey’s tests.
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sented OVA protein. Interestingly, VSSP treatment inhi-
bited cross-presentation of this TAA by both MDSCs
subpopulations (Additional file 6: Figure S6).
To analyze whether OVA cross-presentation by MDSCs
conducted to tolerance of specific CD8+ T cells, OTI CD8+
T cells were cocultured with CD11b+Gr1+ cells isolated
from EG.7 TB mice, inoculated or not with VSSP, in the
absence of exogenous peptide. As expected for the sup-
pressive function of MDSCs, CD11b+Gr1+ cells isolated
from untreated mice bearing EG.7 tumors, that cross-
presented OVA peptide in vivo, failed to activate antigen-
specific CD8+ T cells, measured by the up-regulation of
CD69 molecule (Figure 8A and B). Even though VSSP
interferes with the suppressive mechanisms of MDSCs, in
this experimental setting CD11b+Gr1+ cells obtained from
VSSP-treated EG.7 TB mice did not stimulate OTI lym-
phocytes (Figure 8A and B). This apparent contradictionFigure 8 Tolerogenic MDSCs incubated with VSSP are conditioned to
isolated from EL4 and EG.7 TB mice, inoculated or not with VSSP, were trea
untreated (A and B). To assess the capacity of these cells to accomplish a
from OTI transgenic mice and cocultured at 1:1 ratio with MDSCs for 96 h.
SIINFEKL peptide were used as controls (D and E). Graphs show the perce
CD8+ T cells. ANOVA and Tukey’s tests were used for statistical comparison
were performed.could be associated with the lack of specific peptide in
MHC I complexes from these MDSCs, which is required
to provide the “signal one” to CD8+ T cells. In fact, based
on earlier results indicating that VSSP induces cross-
presentation of OVA protein by DCs in vitro [27], we
tested whether a similar mechanism could be functioning
on MDSCs and this way we could supply the missing
“signal one”. As shown in Figure 8A and C, CD11b+Gr1+
cells isolated from VSSP-injected mice, either bearing EL4
or EG.7 tumors, were unable to cross-present directly
OVA protein in the presence of VSSP in vitro. These
results suggest that VSSP is not capable to potentiate
cross-presentation of OVA protein in vitro by MDSCs.
Only EG.7-induced MDSCs, that cross-presented tumor-
associated OVA peptide in vivo, achieved a moderate
cross-priming of specific CD8+ T cells after incubation
with OVA and VSSP in vitro (Figure 8A and C). Again the
incubation of tolerogenic MDSCs with VSSP transformedcross-prime antigen-specific CD8+ T cells. CD11b+Gr1+ cells
ted in vitro with 10 μg/mL of both OVA and VSSP (A and C) or left
detectable cross-priming, antigen-specific CD8+ T cells were isolated
BM-DCs previously incubated with OVA, OVA and VSSP or pulsed with
ntage of CD69+ cells as a measure of the activation of antigen-specific
of the groups’ mean. Two experiments with similar results
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antigen-specific fashion, probably due to the promotion of
a DCs-like phenotype with increased expression of co-
stimulatory molecules that was demonstrated earlier in
this work. As a positive control, BM-DCs induced a
potent activation of CD8+ T cells as a consequence of
in vitro culture with OVA and VSSP (Figure 8D and E).
Another relevant issue to address was whether adminis-
tration of an OVA-containing vaccine could increase
cross-presentation of this TAA by MDSCs and tolerize ra-
ther than activate tumor-specific CTLs (Additional file 1:
Figure S1D-F). Vaccination with OVA adjuvated in VSSP
inhibited cross-presentation of this antigen by MDSCs in
EG.7 TB mice, whereas immunization with the same pro-
tein in polyI:C did not change the percentage of MDSCs
expressing SIINFEKL peptide (Figure 7C). Noteworthy,
concomitant VSSP administration also significantly in-
hibited cross-presentation of OVA antigen in EG.7 TB
mice vaccinated with this protein adjuvated in polyI:C
(Figure 7C). These results suggest that VSSP could be
used to abrogate cross-presentation of TAA by MDSCs as
a vaccine adjuvant or even employed as an immunomodu-
lator together with other vaccines.
Discussion
There is growing evidence in the literature indicating that
the selection of a suitable adjuvant for cancer vaccines
should pursue beyond the classical characteristics of an ad-
juvant for preventive vaccination. Thus, the additional
property to overcome tumor-induced immunosuppression
is of particular relevance. We have previously shown that a
vaccine containing VSSP protects CTL responses in TB
mice whereas DCs vaccination and polyI:C-based vaccine
both generate reduced CTL responses in comparison to
tumor-free mice [24]. In this work we evidenced that VSSP
is also able to potentiate CTL responses induced by other
vaccine in the immunosuppressive environment promoted
by a tumor. As MDSCs play a key role on tumor-induced
immunosuppression [14,38], the effect of this adjuvant on
the suppressive mechanisms of MDSCs was evaluated.
First we demonstrated that VSSP injection in MCA203 TB
mice impairs the up-regulation of Arg1 and Nos2 gene ex-
pression observed in control MDSCs from untreated TB
mice. Both, the depletion of L-arginine through ARG1 [39]
and the production of peroxynitrite and hydrogen pero-
xide through the coordinated action of NOS2, ARG1 and
NADPH Oxidase [14,40] could cause the down-regulation
of CD3ζ chain. Accordingly, MDSCs from VSSP-treated
TB mice were unable to down-regulate CD3ζ chain on
antigen-specific CD8+ T cells in vitro. Moreover, splenic
CD4+ and CD8+ T cells displayed higher expression of
CD3ζ chain in vivo, as well as CD62L, in TB mice treated
with VSSP, suggesting a smaller degree of impairment of
their activation and functional activity.Tregs play an important role also in tumor-induced im-
munosuppression and it has been described that MDSCs
can further increase this regulatory population [16,17].
Our results indicate that expansion of CD11b+Gr1+ cells
in TB mice, as caused by VSSP, is not necessarily con-
nected to the augment of Tregs. In fact, VSSP administra-
tion reduced the population of splenic Tregs to levels
observed in tumor-free mice, even though the percentage
of MDSCs was 2 fold higher in comparison to untreated
TB mice. In contrast, the inoculation of tumor-free mice
with VSSP did not change the percentage of Tregs, indi-
cating that there is not a direct effect of the adjuvant on
these cells. These results strongly suggest that MDSCs
from VSSP-treated TB mice possess a decreased capacity
to expand Tregs, which could be linked among other fac-
tors to their lower expression of ARG1, enzyme that
seems to be required for this process [17].
Several approaches for the pharmacological targeting of
MDSCs have been studied in pre-clinical and clinical set-
tings [14]. However, to our knowledge only docetaxel [20],
paclitaxel [41] and all-trans retinoic acid [21,22] are able
to induce their differentiation to mature myeloid cells.
This is in our opinion the most desirable choice of inter-
ference with MDSCs function due to the concomitant in-
crease in the number of APCs. In this work we showed
that in vitro VSSP treatment of both tumor-induced
MDSCs and BM-MDSCs was sufficient to increase not
only CD11c marker, typically associated with DCs, but
also the co-stimulatory molecules CD40 and CD86. Fur-
thermore these MDSCs lost their suppressive activity after
incubation with the adjuvant. This in vitro effect of VSSP
connects with the capacity of splenic MDSCs, isolated
from TB mice inoculated with the adjuvant, to potentiate
the Con A-mediated stimulation of IFN-γ production by
tumor-conditioned CD8+ T cells. The optimal stimulation
of T cells caused by Con A requires APCs due to indirect
cross-linking of the TCR [37].
Previous work by Shirota et al. established that CpG
ODN, a TLR9 ligand, induces differentiation of CT26
tumor-induced MDSCs into F4/80+ macrophages, which
display M1 phenotype and possess a significant cytotoxic
activity against CT26 tumor cells [23]. In contrast, incu-
bation of BM-MDSCs with the combination of the TLR4
agonist LPS and IFN-γ increases NO production, poten-
tiates the suppressive activity of MDSCs and impairs
DCs development from this immature population [42].
For polyI:C, which triggers TLR3 signaling, the effect is
less clear. Zoglmeier et al. have shown that this adjuvant
only provokes the conversion of tumor-induced MDSCs
into macrophages in the presence of IFN-α produced by
plasmacytoid DCs [43]. In this work we found that
polyI:C also increased the percentage of CD11c+ cells on
tumor-induced MDSCs and BM-MDSCs, but to a lesser
extent than VSSP. Noteworthy, polyI:C was unable to
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of MDSCs whereas VSSP significantly increased it. In
agreement with Greifenberg et al. [42], LPS was in-
capable to drive a complete differentiation of MDSCs to
mature APCs in our experiments, and CD11b+Gr1+ cells
retained their suppressive function. It is currently ac-
cepted that MDSCs require a first signal inducing their
expansion and a second signal (like TLR signaling) to
fully activate their suppressive mechanisms [44]. All this
emerging evidence of the effect of different TLR ligands
on the suppressive function and differentiation status of
MDSCs reveals their complex interaction, even though
the signaling pathways for TLRs are quite limited.
It has been demonstrated that the spleen is a key organ
for tumor-induced tolerance, in which MDSCs cross-
present TAA to antigen-specific CD8+ T cells in a tolero-
genic fashion [15]. We showed in this work that VSSP was
capable to abrogate cross-presentation of tumor antigens
by splenic MDSCs, whereas polyI:C was unable to modify
this process, indicating a particular characteristic of VSSP.
Furthermore, concomitant administration of VSSP reduced
cross-presentation of a model TAA by splenic MDSCs
derived from TB mice vaccinated with this antigen adju-
vated in polyI:C. To our knowledge this is the first report
of the capacity of an immunomodulator to hamper this
important mechanism for the tolerization of tumor-specific
T cells. The mechanisms leading to antigen cross-presenta-
tion by MDSCs are poorly understood. Our results demon-
strated that VSSP inhibits TAA cross-presentation by the
two main subpopulations of MDSCs, which suggests an ef-
fect of the adjuvant on the mechanism of antigen cross-
presentation itself, and cannot be explain solely by the shift
in the relative amount of M-MDSCs and PMN-MDSCs. In
addition, our previous work indicates that VSSP adminis-
tration significantly reduce the migration of MDSCs to-
wards the tumor site [24], which may help to explain the
inhibition of TAA capture and processing by these cells.
Nonetheless, there are other pathways employed by splenic
MDSCs to capture tumor antigens that should be ad-
dressed in VSSP-treated mice. Amongst these pathways, a
partial involvement of the uptake of tumor exosomes on
TAA cross-presentation has been demonstrated [15,45].
The results of this study also suggest that, in contrast to
DCs, MDSCs are unable to directly cross-present protein
antigens in the presence of VSSP in vitro, an otherwise effi-
cient stimulus for DCs-mediated cross-priming of CD8+
T cells.
The modulation caused by VSSP on several mechanisms
associated with tumor-induced immunosuppression, me-
diated by MDSCs and Tregs, could ultimately contribute
to the observed potentiation of tumor-specific CTL re-
sponses within the tumor site. In line with these results, it
has been reported that MDSCs within the tumor micro-
environment are also more differentiated to mature APCsin TB mice treated with VSSP [24]. These evidences
suggest that, in VSSP-treated mice, the tumor microen-
vironment is more permissive to the antitumor effector
functions of TILs. In fact, VSSP-based vaccines inhibit
tumor growth in MCA203 and EG.7 TB mice [24].
Conclusions
The present work was designed to investigate the immu-
nomodulatory mechanisms of VSSP in TB hosts. In fact,
VSSP treatment not only prevented up-regulation of Arg1
and Nos2 on tumor-induced MDSCs but also reduced
MDSCs-mediated down-regulation of CD3ζ chain on
antigen-specific CD8+ T cells. More importantly, VSSP
abrogated TAA cross-presentation by MDSCs and in-
duced their differentiation on mature DCs. Furthermore,
TB mice treated with VSSP showed lower percentages of
Tregs and more efficient CTL responses. Altogether these
results validate the use of VSSP as immunomodulator,
either as a cancer vaccine adjuvant or in combination
strategies with other immunotherapies.
Methods
Mice
C57BL/6 mice (8 to 12-week-old) were purchased from the
Center for Laboratory Animal Production (CENPALAB,
Havana, Cuba) and OTI TCR transgenic mice were ob-
tained from Charles River Laboratories (Wilmington, MA).
All mice were maintained in the animal house of the
Center of Molecular Immunology (CIM, Havana, Cuba).
The experiments were performed in accordance with in-
stitutional guidelines from the CIM animal care and use
committee.
Reagents and cell lines
VSSP was prepared at CIM by hydrophobic conjugation
of the GM3 ganglioside with outer membrane vesicles
from Neisseria meningitidis strain 385 (Finlay Institute,
Havana, Cuba), as described elsewhere [26]. Chicken OVA
grade VII, Con A from Canavalia ensiformes, LPS from
Escherichia coli, PMA, Ionomycin from Streptomyces con-
globatus and polyI:C were purchased from Sigma-Aldrich
(Saint Louis, MO). OVA257-264 peptide (SIINFEKL) was
synthetized at the Center for Genetic Engineering and
Biotechnology (CIGB, Havana, Cuba) and CFSE was ob-
tained from Invitrogen (Paisley, UK). Recombinant murine
GM-CSF was purchased from PeproTech (NJ, USA). EL4
and EG.7 (EL4 cell line transfected with the gene encoding
for OVA) lymphomas, and MCA203 sarcoma are derived
from C57BL/6 mice (H-2b) and were kindly provided by
Dr. Vincenzo Bronte. The metastatic clone of Lewis lung
carcinoma cell line (3LL-D122) also syngeneic for C57BL/
6 strain was obtained from the American Type Culture
Collection (ATCC, Manassas, VA).
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Cells were stained with specific antibodies or control
isotypes using conventional protocols. The following
anti-mouse antibodies were used for FACS analysis of
MDSCs: CD11b/PECy5, Gr1/PE, Gr1/APC, CD62L/
FITC, F4/80/FITC, CD11c/PE, and MHC CI OVA pep-
tide/Biotin from eBiosciences (San Diego, CA); as well
as CD124/PE, CD40/FITC, CD86/FITC, IA-IE/FITC,
Ly6C/FITC and Ly6G/PE that were purchased from BD
Biosciences (San Jose, CA). Lymphocytes characteri-
zation was performed with the next specific antibodies:
CD8/PE and CD8/Biotin, CD69/PECy5, CD62L/FITC,
CD247/PE, CD4/PE, CD4/PECy5, CD25/PECy5, Foxp3/
Biotin, IFN-γ/FITC, IL-4/PE and IL-17/PE, all from
eBiosciences. FITC-conjugated Streptavidin was pur-
chased also from eBiosciences. In all cases, cells were
previously incubated with anti-mouse FcγR 2.4G2 asci-
tes (HB-197; ATCC) to reduce the non-specific binding.
For intracellular staining, cells were fixed and perme-
abilized, according to the manufacturer’s protocol, with
either Foxp3 Staining Buffer Set or IC Fixation and 10X
Permeabilization Buffers from eBiosciences. Cells were
acquired using both FACScan (BD Biosciences) and
Gallios (Beckman Coulter, Miami, FL) flow cytometers
and analyzed with Kaluza 1.2 (Beckman Coulter) and
FlowJo 5.7.2 (Tree Star Inc., USA) softwares.Generation of BM-derived MDSCs and DCs
BM cells were harvested from femurs and tibias of
C57BL/6 mice. For DCs preparation, the cells were cul-
tured for 6 days with 20 ng/mL of GM-CSF as described
elsewhere [46]. BM-MDSCs were obtained in Petri
dishes after a 4 days incubation of 2.5×105 BM cells
with 40 ng/mL of GM-CSF. Additionally, VSSP was
added during MDSCs differentiation at a concentration
of 10 μg/mL.Immunization protocols
To evaluate the immunomodulatory properties of VSSP,
C57BL/6 mice were s.c. challenged on day 0 with 1×106
cells of MCA203, EL4 or EG.7 tumor lines. VSSP
(200 μg/mice) was next administered on days 11, 12
and 18 to MCA203 TB mice. Likewise, mice with EL4
and EG.7 tumors were inoculated on days 4, 5 and 11
with the adjuvant. In some experiments mice received a
vaccine containing OVA protein (1 mg/mice) mixed
with either VSSP or polyI:C (100 μg/mice). PolyI:C was
given on days 13, 14 and 15 for MCA203 tumor model
and 4, 5 and 6 in EG.7 TB mice. All experiments were
performed on days 22 and 13 for MCA203 and EL4 (or
EG.7) tumor models, respectively. Immunization proto-
cols were summarized and depicted in Additional file 1:
Figure S1.Modulation of Th differentiation and CTL responses
by VSSP
The analysis of tumor-specific Th responses was per-
formed by 96 h stimulation of 4×105 splenocytes, from
VSSP-treated or untreated MCA203 TB mice, with 2×104
BM-DCs. These BM-DCs were previously pulsed with
tumor lysates obtained from 10×106 cells of MCA203 and
3LL-D122 tumor lines. On the last 10 h, PMA (50 ng/mL)
and Ionomycin (500 ng/mL) were added to the culture,
together with the Golgi blocking reagent Monensin (as
recommended by the manufacturer, eBiosciences). IFN-γ,
IL-17 and IL-4 were measured by intracellular staining as
describe above.
To evaluate the in vivo antigen-specific CTL response in
vaccinated TB mice, splenocytes from naive mice were dif-
ferentially labeled (5 min at 37°C) with CFSE. The cells
stained with CFSEhigh (5 μM) were used as targets and
pulsed with SIINFEKL peptide (1 μM; 90 min at 37°C and
5% CO2), whereas the cells labeled with CFSE
low
(0.33 μM) were kept unpulsed and served as internal con-
trol. After extensive washing to remove free peptide, tar-
get and control cells were mixed at 1:1 proportion and
coinjected i.v. into vaccinated mice. Sixteen hours later, in-
guinal draining lymph nodes were harvested and the total
events corresponding to both fluorescent intensities
(CFSElow and CFSEhigh) were determined by FACS. The
percentage of specific lysis was calculated as: 100 −
[(CFSEhigh/CFSElow) × 100].
MDSCs isolation and in vitro differentiation to APCs
Spleens from TB mice, treated or not with VSSP, were har-
vested and single-cell suspensions prepared. MDSCs were
isolated using magnetic microbeads conjugated with rat
anti-mouse/human CD11b mAb (Miltenyi Biotec, Bergisch
Gladbach, Germany), following the manufacturer’s instruc-
tions. Purity of the cell population was evaluated by FACS
and exceeded 95%. More than 96% of isolated CD11b+
cells expressed Gr1 marker, which excluded any relevant
contamination with conventional DCs or macrophages
(data not shown).
To assess differentiation of MDSCs into APCs, 1×106
splenic CD11b+Gr1+ cells or BM-MDSCs were cultured
for 24 h in 6 well plates (BD Falcon, Oxford, UK) with
VSSP (10 μg/mL), polyI:C (30 μg/mL), LPS (1 μg/mL),
or left untreated. Molecules associated with DCs lineage,
as well as markers of mature APCs, were detected by
FACS within the CD11b+Gr1+ gate. Suppressive capacity
of these cells was compared as indicated below.
In vitro MDSCs-mediated suppression assay
Splenocytes (6×105) from naive mice were stained with
2 μM of CFSE and cocultured with splenic CD11b+Gr1+
cells or BM-MDSCs, at different effector to suppressor
ratios, in 96-well flat bottom plates (BD Falcon). T cells
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Proliferation was measured by CFSE dilution after 96 h
of culture.
Down-regulation of CD3ζ chain by MDSCs
The down-regulation of CD3ζ chain caused by MDSCs
was analyzed by culturing 6×105 splenocytes from OTI
transgenic mice with 1.2×105 MDSCs, isolated from
VSSP-treated or untreated MCA203 TB mice, in 96-well
flat bottom plates (BD Falcon). OTI CD8+ cells were sti-
mulated with 1 μM of SIINFEKL peptide for 72 h. The ex-
pression of CD3ζ chain on these CD8+ cells was analyzed
by intracellular staining using the anti-mouse CD247/PE
antibody. In addition, the down-regulation of CD3ζ and
CD62L on splenic T cells was detected in vivo in mice
with MCA203 tumors, treated or not with VSSP. The per-
centage of MFI reduction for CD3ζ and CD62L molecules
was calculated as indicated in the formula: (MFIPBS–
MFIMCA203 or MCA203 + VSSP)/MFIPBS * 100. Afterward these
data were normalized by the percentage of MDSCs in each
mouse, in order to study the in vivo function of MDSCs at
equivalent amounts.
Real-time PCR
Total RNA extraction and real-time analysis were per-
formed as previously described [24]. Data analyses were
done with SDS 2.3 software.
Restoration of MDSCs as functional APCs
The activity of MDSCs as functional APCs was evaluated
through their capacity to potentiate Con A-induced
stimulation of CD8+ T cells. IFN-γ secretion was mea-
sured in a classical ELISPOT assay in which cellulose-
ester membrane microplates (Millipore, Milan, Italy) were
coated with R4-6A2 mAb (BD Biosciences). Both CD8+
cells and MDSCs were positively selected from the spleens
of TB mice using magnetic microbeads (Miltenyi Biotec)
and following the manufacturer’s instructions. Purified
CD8+ T cells (5×104) were next stimulated for 72 h with
2 μg/mL of Con A in the presence of 2×104 CD11b+Gr1+
cells. Plates were washed extensively, and spots were
visualized with biotin-conjugated mAb XMG1.2 (BD
Biosciences), alkaline phosphatase-conjugated goat anti-
biotin antibody (Vector Laboratories, Peterborough, U.K.)
and AP Substrate Kit (Bio-Rad Laboratories, Hempstead,
U.K.). The number of spots was counted in triplicate and
calculated using an automatic ELISPOTcounter (ELISPOT
Reader System ELRIFL04; AID, Straßberg, Germany).
Functional analysis of TILs
MCA203 tumors from untreated or VSSP-inoculated mice
were extracted on day 22 and TILs were isolated with
microbeads conjugated with either anti-CD90 or anti-CD8
mAbs. To evaluate the tumor-specific response of CD8+TILs, isolated CD8+ T cells (5×104) were stimulated for
72 h with 1×105 MCA203 cells, or MB16F10 negative
control, both previously treated with IFN-α to increase
MHC I expression. Non-specific stimulation of TILs with
2 μg/mL of Con A mitogen was additionally performed
during 72 h. IFN-γ production was detected by ELISPOT
assay as described above.
Cross-presentation of TAA by MDSCs
Mice bearing EG.7 tumors inoculated with VSSP alone,
and either OVA/VSSP or OVA/polyI:C vaccines, were
euthanized and splenocytes stained with mAbs specific
for CD11b, Gr1 and SIINFEKL peptide bound to H-2Kb.
Splenocytes from EL4 TB mice served as negative con-
trols for the expression of OVA antigen.
For assessing the capacity of splenic MDSCs to achieve
an effective cross-priming, antigen-specific CD8+ T cells
were isolated from OTI transgenic mice by negative selec-
tion using CD8a+ T Cell Isolation Kit II (Miltenyi Biotec)
and used as effector cells. Splenic MDSCs isolated from
EG.7 and EL4 TB mice, inoculated or not with VSSP, were
cultured at 1×106 cells per well with 10 μg/mL of both
OVA and VSSP for 24 h, or left untreated. Afterward,
MDSCs were washed and cocultured at 1:1 ratio with
1×105 OTI CD8+ cells for 96 h in 96-well flat bottom plates
(BD Falcon). BM-DCs previously incubated with OVA,
OVA and VSSP or pulsed with SIINFEKL peptide were
used as controls. As a measure of CD8+ T cell activation,
the expression of CD69 molecule was detected by FACS.
Statistics
Equality of variances was analyzed with Bartlett’s test and
Kolmogorov-Smirnov test was used to verify normal distri-
bution of data. Comparisons of CD62L expression on T
cells, IFN-γ secretion from TILs and changes in CD11c
molecule on MDSCs in vitro were performed with Student’s
t test (2-tailed), whereas the data regarding the down-
regulation of CD3ζ chain in vivo was analyzed with
Mann-Whitney’s U test. Statistical significance in the
comparison of Th differentiation was tested by Kruskal-
Wallis and Dunn’s non-parametric tests. All other statis-
tical analyses were performed with one-way ANOVA and
Tukey’s test for pairwise comparison, using SPSS 16.0 soft-
ware (SPSS, Chicago, IL). The statistically significant dif-
ferences (p < 0.05) between more than two groups were
always represented within the graphs by diverse letters.
Additional files
Additional file 1: Figure S1. Schematic representation of the treatment
protocols to evaluate the immunomodulatory properties of VSSP.
MCA203 tumors were implanted s.c. in the flank of C57BL/6 mice, on day
0, and a group of TB mice additionally received three doses of VSSP on
days 11, 12 and 18. (A) To evaluate in vivo CTL responses potentiated by
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with OVA adjuvated in polyI:C on days 13, 14 and 15. (B) Spleens from
MCA203 TB mice, treated or not with VSSP, were harvested on day 22
and the percentage, inhibitory function and characterization of MDSCs
suppressive mechanisms were addressed. This protocol was used likewise
to determine percentages of Tregs, as well as CD3ζ chain and CD62L
expression on T lymphocytes. Splenocytes from these mice were also
tested to study the modulation caused by VSSP on tumor-induced
polarization of Th cells specific for TAA. (C-F) C57BL/6 mice were s.c.
challenged with EL4 or EG.7 tumor cells on day 0. (C) EG.7 TB mice, as
well as control mice with EL4 tumors, were inoculated on days 4, 5 and
11 with VSSP, to measure on day 13 the effect of the adjuvant on
cross-presentation of TAA by splenic MDSCs. (D-E) To assess whether
administration of an OVA-containing vaccine could change cross-presentation
of this TAA by MDSCs, EG.7 TB mice were immunized with OVA protein mixed
with either VSSP (D) or polyI:C (E). VSSP-containing vaccine was
administered on days 4, 5 and 11 (D) whereas the vaccine employing polyI:C
was inoculated on days 4, 5 and 6 (E). (F) Another group of EG.7 TB mice was
vaccinated with OVA adjuvated in polyI:C on days 4, 5 and 6 and additionally
received three doses of VSSP (days 4, 5 and 11). On day 13, the modulatory
effect of VSSP on cross-presentation of this TAA (OVA) by splenic MDSCs was
evaluated on vaccinated EG.7 TB mice.
Additional file 2: Figure S2. Effect of VSSP treatment on the
phenotype and suppressive activity of MCA203-induced splenic MDSCs.
MCA203 tumors were s.c. grown in C57BL/6 mice and both tumor-free
and TB mice were inoculated three times with VSSP. Another group of
animals with tumors remained untreated. (A) CD11b+Gr1+ cells were
enriched from pools of spleens by magnetic microbeads and stained
with the indicated antibodies. From top to bottom panel: FACS profile of
MDSCs from VSSP-treated tumor-free mice, MCA203 TB mice, and mice
with MCA203 tumors inoculated with VSSP. (B) To evaluate the inhibition
of CD8+ T cell responses, 20% MDSCs were incubated for 72 h with
4×105 SIINFEKL-pulsed splenocytes isolated from tumor-free mice
previously inoculated with OVA mixed with polyI:C. The IFN-γ production
was detected by a classical ELISPOT assay and the number of IFN-γ spots
per 105 CD8+ T cells is indicated in the graph. (C) 2×104 effector
splenocytes were cocultured with 1×105 SIINFEKL-pulsed EL4 target cells
or non-pulsed controls, in the presence of 20% MDSCs. Target cells were
pre-treated with 25 μg/mL of Mitomycin C to avoid proliferation. After
92 h of culture, supernatans were recovered and the release of lactate
de-hydrogenase (LDH) measured as recommended by the manufacturer
(Roche Diagnostics, Indianapolis, IN). Mean percentage of specific lysis
from triplicate wells was determined by the formula: % cytotoxicity =
[(experimental − spontaneous LDH release)/(maximum − spontaneous LDH
release)] × 100. (B-C) Statistically significant differences were detected with
ANOVA and Tukey’s tests. These results are representative of at least two
experiments.
Additional file 3: Figure S3. Differentiation of MDSCs isolated from
different TB mice due to incubation with VSSP in vitro. CD11b+Gr1+ cells
isolated from the spleen of MCA203 (A) and EG.7 (B) TB mice were
cultured with 10 μg/mL VSSP for 24 h, or left untreated. Histograms show
the expression of the molecules CD11c, CD11b, CD40 and CD86 detected
by FACS within the gate of CD11b+Gr1+ cells. Two repetitions of this
experiment were done with similar outcome.
Additional file 4: Figure S4. Comparative effect of VSSP, polyI:C and
LPS on differentiation of EL4-induced MDSCs towards DCs in vitro.
(A) VSSP (10 μg/mL), (B) polyI:C (30 μg/mL) and (C) LPS (1 μg/mL) were
added in vitro to EL4-induced MDSCs for 24 h. Afterwards, cells were
washed and stained with anti-mouse Abs specific for CD11c, CD11b, Gr1
and CD40 markers. Untreated tumor-induced MDSCs were included as
control of immature population. Histograms are referred to the gate of
CD11b+Gr1+ cells. The results shown in this figure are representative of
two similar experiments.
Additional file 5: Figure S5. Phenotypic characterization of MDSCs
generated in vitro from BM precursors, in the presence or absence of
VSSP. BM-precursors were cultured during 4 days with 40 ng/mL of
GM-CSF. VSSP (10 μg/mL) was added through the complete time of
culture, together with GM-CSF. The pseudocolor graphs show the
staining with CD11b, Gr1, F4/80, Ly6G and IL-4Rα on MDSCs generatedby both culture conditions. This experiment was done twice and compar-
able effect was observed.
Additional file 6: Figure S6. Effect of VSSP on cross-presentation of
TAA by PMN-MDSCs and M-MDSCs. Mice bearing EL4 or EG.7 tumors
were injected with VSSP and cross-presentation of the OVA peptide
SIINFEKL was detected, two days after the last VSSP injection, on splenic
PMN-MDSCs (CD11b+Gr1hi) and M-MDSCs (CD11b+Gr1lo). (A) Gaiting
strategy followed to design MDSCs subpopulations is shown for one
representative mouse per group. Typical histograms corresponding to the
staining with the mAb specific for MHC I-SIINFEKL complexes on each MDSCs
subpopulation are also depicted. (B-C) Mean ± SD of the percentage of
PMN-MDSCs (B) and M-MDSCs (C) expressing OVA peptide bound to MHC I
molecules (n = 9 mice per group belonging to two different experiments).
Diverse letters indicate statistically significant differences by ANOVA and
Tukey’s tests.
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